Search

Your search keyword '"Whitlock, James A."' showing total 646 results
Start Over Author "Whitlock, James A."
646 results on '"Whitlock, James A."'

105. Familial clustering of Langerhans cell histiocytosis

Author

Aricò, Maurizio, Nichols, Kim, Whitlock, James A., Arceci, Robert, Haupt, Riccardo, Mittler, Uwe, Kühne, Thomas, Lombardi, Alessandra, Ishii, Eiichi, Egeler, R. Maarten, and Danesino, Cesare

Published
1999

108. High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Author

Gupta, Sumit, primary, Alexander, Sarah, additional, Zupanec, Sue, additional, Athale, Uma, additional, Bassal, Mylene, additional, Edwards, Ethan, additional, Gibson, Paul J., additional, Johnston, Donna, additional, Marjerrison, Stacey, additional, Zorzi, Alexander, additional, Hitzler, Johann K., additional, Naqvi, Ahmed, additional, Punnett, Angela, additional, Whitlock, James A., additional, Grupp, Stephan A., additional, Maude, Shannon L., additional, and Krueger, Joerg, additional

Published
2018
Full Text
View/download PDF

112. Epipodophyllotoxin-related leukemia: identification of a new subset of secondary leukemia

Author

Whitlock, James A., Greer, John P., and Lukens, John N.

Subjects
Podophyllotoxin -- Adverse and side effects, Etoposide -- Adverse and side effects, Leukemia -- Causes of, Chemotherapy -- Adverse and side effects, Health
Abstract

It is known that some chemotherapeutic agents are capable of causing cancer, as well as destroying it. The majority of cases of secondary cancer that have resulted from chemotherapeutic treatment have been caused by alkylating agents. This highly reactive group of chemical compounds works by reacting with DNA and adding methyl groups to its chemical structure. In a small number of cases these chemical reactions may cause a mutation that leads to cancer. However, evidence is accumulating that suggests other forms of chemotherapy may also cause cancer in a small fraction of cases. Nonalkylating chemotherapeutic agents that have been linked with cancer include etoposide and teniposide. These compounds are called epipodophyllotoxins and are derived from a substance that occurs naturally in plants. The epipodophyllotoxins work by inhibiting an enzyme called DNA topoisomerase II, which reversibly cleaves DNA chains as a part of a cell's normal management of the twisted and coiled DNA chain. When this enzyme is inhibited, DNA breaks accumulate, and the cell dies. In a recent case, a 22-month-old girl developed a mass in the lower spine that was diagnosed as a yolk-sac tumor. Treatment with vinblastine, bleomycin, cisplatin, and etoposide was successful. However, a little more than one year later the child developed acute monoblastic leukemia. The patient remains in remission 15 months after chemotherapy for the leukemia. This case adds to the 36 cases already published in the medical literature in which leukemia developed in a patient treated with etoposide or teniposide. The cases differed from the secondary leukemias that follow treatment with alkylating agents. In the reviewed cases, leukemia developed an average of 33 months after epipodophyllotoxin use, and an average of 58 to 73 months after alkylating agents. The leukemia following epipodophyllotoxin use was usually of the monocytic or myelomonocytic type. A particular chromosome abnormality seems to be especially common among these patients; about half of the cases had some abnormality involving chromosome 11, specifically 11q23. It is not yet known if the agents commonly used with epipodophyllotoxins, such as cisplatin, might enhance the development of leukemia. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

114. Relation of silent myocardial ischemia after coronary artery bypass grafting t angiographic completeness of revascularization and long-term prognosis

Author

Kennedy, Harold L., Seiler, Sondra M., Sprague, Michael K., Homan, Sharon M., Whitlock, James A., Kern, Morton J., Vandormael, Michel G., Barner, Hendrick B., Codd, John E., Willman, Vallee L., and Lyyski, Debra

Subjects
Coronary heart disease -- Prognosis, Silent myocardial ischemia -- Risk factors, Angiography -- Evaluation, Coronary artery bypass -- Research, Myocardial revascularization -- Research, Health
Abstract

The prevalence and characteristics of silent ischemia (inadequate blood flow to the heart muscle due to constriction or obstruction of coronary arteries, without symptoms) was assessed in patients who had a CABG, or coronary artery bypass graft performed. Following surgery the patients were monitored for 62 months. A number of complications may account for myocardial ischemia after CABG, but it is not known to what extent these factors influence long-term prognosis. Ninety-four individuals were examined by 24-hour ambulatory electrocardiography (ECG) for ST-segment depressions (an abnormal ECG reading indicating a type of heart attack) one to three months after the procedure. Another 184 patients were examined at 12 months. Silent ischemia was also compared with results of angiographies (X-rays of blood vessels that use a radiopaque contrast agent) which were performed to evaluate revascularization of the heart and subsequent adverse reactions. At the early follow-up, 20 percent of the patients had silent ischemia; at the late follow-up, silent ischemia was detected in 27 percent of the patients. No association between CABG and silent ischemia was found, and in patients who had recent CABG silent ischemia was not considered to be predictive of a poor long-term prognosis. Age was the only characteristic that was associated with high risk for additional cardiac disease. It was concluded that in patients with good left ventricular function (effectively pumping blood to the body), an adverse prognosis is not associated with silent ischemia as detected by 24-hour ambulatory ECG one year after CABG surgery.

Published
1990

115. National Impact of the EPEC-Pediatrics Enhanced Train-the-Trainer Model for Delivering Education on Pediatric Palliative Care

Author

Widger, Kimberley, primary, Wolfe, Joanne, additional, Friedrichsdorf, Stefan, additional, Pole, Jason D., additional, Brennenstuhl, Sarah, additional, Liben, Stephen, additional, Greenberg, Mark, additional, Bouffet, Eric, additional, Siden, Harold, additional, Husain, Amna, additional, Whitlock, James A., additional, Leyden, Myra, additional, and Rapoport, Adam, additional

Published
2018
Full Text
View/download PDF

116. Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.

Author

Kieran, Mark W., primary, Bouffet, Eric, additional, Broniscer, Alberto, additional, Cohen, Kenneth J., additional, Geoerger, Birgit, additional, Hansford, Jordan R., additional, Hingorani, Pooja, additional, Aerts, Isabelle, additional, Andre, Nicolas, additional, Bertozzi-Salamon, Anne-Isabelle, additional, Dunkel, Ira J., additional, Hummel, Trent Ryan, additional, Leary, Sarah, additional, Moreno, Lucas, additional, Russo, Mark W., additional, Tseng, Lillian, additional, Dasgupta, Kohinoor, additional, Nebot, Noelia, additional, Whitlock, James, additional, and Hargrave, Darren R, additional

Published
2018
Full Text
View/download PDF

117. Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.

Author

McCowage, Geoffrey Brian, primary, Mueller, Sabine, additional, Pratilas, Christine A., additional, Hargrave, Darren R, additional, Moertel, Christopher L., additional, Whitlock, James, additional, Fox, Elizabeth, additional, Hingorani, Pooja, additional, Russo, Mark W., additional, Dasgupta, Kohinoor, additional, Tseng, Lillian, additional, Mookerjee, Bijoyesh, additional, and Geoerger, Birgit, additional

Published
2018
Full Text
View/download PDF

118. Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).

Author

Geoerger, Birgit, primary, Moertel, Christopher L., additional, Whitlock, James, additional, McCowage, Geoffrey Brian, additional, Kieran, Mark W., additional, Broniscer, Alberto, additional, Hargrave, Darren R, additional, Hingorani, Pooja, additional, Kilburn, Lindsay Baker, additional, Mueller, Sabine, additional, Tseng, Lillian, additional, Nebot, Noelia, additional, Dasgupta, Kohinoor, additional, Russo, Mark W., additional, and Fox, Elizabeth, additional

Published
2018
Full Text
View/download PDF

119. Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.

Author

Skamene, Tanya, primary, Siu, Lillian L., additional, Renouf, Daniel John, additional, Laskin, Janessa J., additional, Bedard, Philippe L., additional, Jones, Steven J. M., additional, Ferrario, Cristiano, additional, Whitlock, James, additional, Petrie, Joan, additional, Sullivan, Patrick, additional, Malone, Eoghan Ruadh, additional, Nomikos, Dora, additional, Chen, Bingshu E., additional, and Dancey, Janet, additional

Published
2018
Full Text
View/download PDF

121. DEVELOPMENT OF A PLAN FOR AN INTENSIVE STUDY OF AUTOMATION AND ITS IMPLICATIONS FOR EDUCATION.

Author

George Peabody Coll. for Teachers, Nashville, TN. and WHITLOCK, JAMES W.

Abstract

A DETAILED STUDY MODEL WAS DEVELOPED FOR COMMUNITY USE IN STUDIES OF AUTOMATION AND ITS IMPLICATIONS FOR THE EDUCATIONAL PROCESS. THREE SPECIFIC STEPS WERE INVOLVED IN DEVELOPING THIS MODEL--(1) A COMPREHENSIVE STUDY PLAN WAS DEVELOPED WHICH INCLUDED THE SPECIFIC DATA TO BE COLLECTED, AND DESIGN AND ANALYTICAL PROCEDURES FOR THE COLLECTION PROCESS, (2) THE STUDY PLAN WAS TRIED OUT IN A PILOT SITUATION AND LOCATION, NAMELY, THE NASHVILLE-DAVIDSON COUNTY METROPOLITAN AREA IN TENNESSEE, AND (3) THE STUDY PLAN WAS THEN REVISED ON THE BASIS OF PILOT EXPERIENCES. FOUR MAJOR FACETS OF INVESTIGATION TO BE CONSIDERED WERE INCLUDED IN THE FINAL STUDY PLAN OR MODEL--(1) BASIC BACKGROUND INFORMATION ON THE COMMUNITY, (2) THE EXTENT TO WHICH COMMUNITY INDUSTRIES ARE AUTOMATING, THE NATURE OF AUTOMATED JOBS IN THE COMMUNITY, AND THE EDUCATIONAL AND TRAINING REQUIREMENTS OF THESE AUTOMATED JOBS, (3) THE STATUS OF ELEMENTARY, SECONDARY, OUT-OF-SCHOOL, AND ADULT EDUCATION PROGRAMS AND PERSONNEL IN THE COMMUNITY AND OF CURRENT VOCATIONAL AND TECHNICAL EDUCATIONAL OPPORTUNITIES IN THE COMMUNITY, AND (4) THE CHANGES IN THE PROGRAM OF EDUCATION WHICH ARE DICTATED BY THE CHANGING REQUIREMENTS OF AUTOMATION. (JH)

Published
1965

123. Benzo[a]pyrene Metabolism: Enzymatic and Liquid Chromatographic Analysis and Application to Human Liver, Lymphocytes, and Monocytes

Author

Gelboin, Harry V., Selkirk, James, Okuda, Takao, Nemoto, Nobuo, Yang, Shen K., Wiebel, Friedrich J., Whitlock, James P., Jr., Rapp, Herbert J., Bast, Robert C., Jr., Jollow, David J., editor, Kocsis, James J., editor, Snyder, Robert, editor, Vainio, Harri, editor, Saukkonen, Jussi, editor, Witmer, Charlotte, editor, and Walle, Thomas, editor

Published
1977
Full Text
View/download PDF

128. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)

Author

Rheingold, Susan R., primary, Tasian, Sarah K., additional, Whitlock, James A., additional, Teachey, David T., additional, Borowitz, Michael J., additional, Liu, Xiaowei, additional, Minard, Charles G., additional, Fox, Elizabeth, additional, Weigel, Brenda J., additional, and Blaney, Susan M., additional

Published
2017
Full Text
View/download PDF

129. Optimizing Autologous Mononuclear Cell Collections for Cellular Therapy Using the Novel Optia Apheresis Device in Pediatric Patients with High Risk Leukemia

Author

Even-Or, Ehud, primary, Di Mola, Maria, additional, Ali, Muhammad, additional, Courtney, Sarah, additional, McDougall, Elizabeth, additional, Alexander, Sarah, additional, Schechter, Tal, additional, Whitlock, James, additional, Licht, Christoph, additional, and Krueger, Joerg, additional

Published
2017
Full Text
View/download PDF

130. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

von Stackelberg, Arend, primary, Locatelli, Franco, additional, Zugmaier, Gerhard, additional, Handgretinger, Rupert, additional, Trippett, Tanya M., additional, Rizzari, Carmelo, additional, Bader, Peter, additional, O’Brien, Maureen M., additional, Brethon, Benoît, additional, Bhojwani, Deepa, additional, Schlegel, Paul Gerhardt, additional, Borkhardt, Arndt, additional, Rheingold, Susan R., additional, Cooper, Todd Michael, additional, Zwaan, Christian M., additional, Barnette, Phillip, additional, Messina, Chiara, additional, Michel, Gérard, additional, DuBois, Steven G., additional, Hu, Kuolung, additional, Zhu, Min, additional, Whitlock, James A., additional, and Gore, Lia, additional

Published
2016
Full Text
View/download PDF

131. D03-D Quality of Palliative Care for Children with Cancer

Author

Widger, Kimberley, primary, Friedrichsdorf, Stefan, additional, Wolfe, Joanne, additional, Liben, Stephen, additional, Pole, Jason D., additional, Bouffet, Eric, additional, Greenberg, Mark, additional, Husain, Amna, additional, Siden, Harold, additional, Whitlock, James A., additional, and Rapoport, Adam, additional

Published
2016
Full Text
View/download PDF

132. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis

Author

Arceci, Robert J., primary, Allen, Carl E., additional, Dunkel, Ira J., additional, Jacobsen, Eric, additional, Whitlock, James, additional, Vassallo, Robert, additional, Morris, Shannon R., additional, Portnoy, Alison, additional, Reedy, Beth Ann, additional, Smith, Deborah A., additional, Noble, Robert, additional, Murnane, Amy, additional, Cornfeld, Mark, additional, Rodriguez-Galindo, Carlos, additional, Heaney, Mark L., additional, McClain, Kenneth, additional, and Vaiselbuh, Sarah, additional

Published
2016
Full Text
View/download PDF

134. Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2

Author

Raetz, Elizabeth A., Cairo, Mitchell S., Borowitz, Michael J., Lu, Xiaomin, Devidas, Meenakshi, Reid, Joel M., Goldenberg, David M., Wegener, William A., Zeng, Hui, Whitlock, James A., Adamson, Peter C., Hunger, Stephen P., and Carroll, William L.

Subjects
Adult, Male, Adolescent, Remission Induction, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antibodies, Monoclonal, Humanized, Prognosis, Combined Modality Therapy, Article, Cohort Studies, Young Adult, Child, Preschool, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Immunotherapy, Neoplasm Recurrence, Local, Child, Follow-Up Studies, Neoplasm Staging
Abstract

Given the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-lymphoblastic leukemia (B-ALL) and early bone marrow relapse.Therapy consisted of three established blocks of re-induction chemotherapy. Epratuzumab (360 mg/m(2)/dose) was combined with chemotherapy on weekly × 4 (B1) and twice weekly × 4 [eight doses] (B2) schedules during the first re-induction block. Remission rates and minimal residual disease (MRD) status were compared to historical rates observed with the identical chemotherapy platform alone.CR2 was achieved in 65 and 66%, of the evaluable B1 (n = 54) and B2 patients (n = 60), respectively; unchanged from that observed historically without epratuzumab. Rates of MRD negativity (0.01%) were 31% in B1 (P = 0.4128) and 39% in B2 patients (P = 0.1731), compared to 25% in historical controls. The addition of epratuzumab was well tolerated, with a similar toxicity profile to that observed with the re-induction chemotherapy platform regimen alone.Epratuzumab was well tolerated in combination with re-induction chemotherapy. While CR2 rates were not improved compared to historical controls treated with chemotherapy alone, there was a non-significant trend towards improvement in MRD response with the addition of epratuzumab (twice weekly for eight doses) to re-induction chemotherapy.

Published
2015

135. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

Author

Niewerth, Denise, primary, Kaspers, Gertjan J. L., additional, Jansen, Gerrit, additional, van Meerloo, Johan, additional, Zweegman, Sonja, additional, Jenkins, Gaye, additional, Whitlock, James A., additional, Hunger, Stephen P., additional, Lu, Xiaomin, additional, Alonzo, Todd A., additional, van de Ven, Peter M., additional, Horton, Terzah M., additional, and Cloos, Jacqueline, additional

Published
2016
Full Text
View/download PDF

138. Protocol: Evaluating the impact of a nation-wide train-the-trainer educational initiative to enhance the quality of palliative care for children with cancer

Author

Widger, Kimberley, primary, Friedrichsdorf, Stefan, additional, Wolfe, Joanne, additional, Liben, Stephen, additional, Pole, Jason D., additional, Bouffet, Eric, additional, Greenberg, Mark, additional, Husain, Amna, additional, Siden, Harold, additional, Whitlock, James A., additional, and Rapoport, Adam, additional

Published
2016
Full Text
View/download PDF

139. Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium

Author

Sun, Weili, primary, Malvar, Jemily, additional, Sposto, Richard, additional, Verma, Anupam, additional, Wilkes, Jennifer J., additional, Dennis, Robyn M., additional, Heym, Kenneth Matthew, additional, Eckroth, Elena, additional, Vandergiesse, Jeannette, additional, Gaynon, Paul S., additional, Wayne, Alan S., additional, and Whitlock, James A., additional

Published
2015
Full Text
View/download PDF

140. Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Author

Shukla, Neerav, primary, O'Brien, Maureen M., additional, Silverman, Lewis B., additional, Pauly, Melinda, additional, Wetmore, Cynthia, additional, Loh, Mignon L., additional, Whitlock, James A., additional, Brown, Patrick, additional, Thomson, Blythe, additional, Blakemore, Stephen J., additional, Daigle, Scott, additional, Pimentel, Patricia, additional, Waters, Nigel J., additional, Krivstov, Andrei V, additional, Koche, Richard, additional, Armstrong, Scott A., additional, Ho, Peter T, additional, and Gore, Lia, additional

Published
2015
Full Text
View/download PDF

141. Children’s Oncology Group’s 2013 Blueprint for Research: Acute Lymphoblastic Leukemia

Author

Hunger, Stephen P., Loh, Mignon L., Whitlock, James A., Winick, Naomi J., Carroll, William L., Devidas, Meenakshi, and Raetz, Elizabeth A.

Subjects
Clinical Trials as Topic, Risk Factors, Research, Humans, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Article
Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

Published
2012

142. A Multi-Center Phase Ib Study of Oxaliplatin (NSC#266046) in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors

Author

Macy, Margaret E., Duncan, Tracey, Whitlock, James, Hunger, Stephen P., Boklan, Jessica, Narendren, Aru, Herzog, Cynthia, Arceci, Robert J., Bagatell, Rochelle, Trippett, Tanya, Christians, Uwe, Rolla, Katherine, Ivy, S. Percy, and Gore, Lia

Subjects
Male, Adolescent, Dose-Response Relationship, Drug, Maximum Tolerated Dose, Organoplatinum Compounds, Leucovorin, Article, Oxaliplatin, Child, Preschool, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Fluorouracil, Child
Abstract

Platinum agents have been used for a variety of cancers, including pivotal use in pediatric tumors for many years. Oxaliplatin, a third generation platinum, has a different side effect profile and may provide improved activity in pediatric cancers.Patients 21 years or younger with progressive or refractory malignant solid tumors, including tumors of the central nervous system were enrolled on this multi-center open label, non-randomized Phase 1 dose escalation study. The study used a standard 3 + 3 dose escalation design with 2 dose levels (85 and 100 mg/m(2) ) with an expansion cohort of 15 additional patients at the recommended dose. Patients received oxaliplatin at the assigned dose level and 5-fluorouracil (5-FU) bolus 400 mg/m(2) followed by a 46-hour 5-FU infusion of 2,400 mg/m(2) every 14 days. The leucovorin dose was fixed at 400 mg/m(2) for all cohorts.Thirty-one evaluable patients were enrolled, 8 at 85 mg/m(2) and 23 at 100 mg/m(2) for a total of 121 courses. The median age was 12 years (range 2-19 years). The main toxicities were hematologic, primarily neutrophils and platelets. The most common non-hematologic toxicities were gastrointestinal. Stable disease was noted in 11 patients (54% of evaluable patients) and 1 confirmed partial response in a patient with osteosarcoma.The maximum planned dose of oxaliplatin at 100 mg/m(2) per dose in combination with 5-FU and leucovorin was safe and well tolerated and in this patient population. This combination demonstrated modest activity in patients with refractory or relapsed solid tumor and warrants further study. Pediatr Blood Cancer 2013;60:230-236. © 2012 Wiley Periodicals, Inc.

Published
2012

144. Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children’s Oncology Group study.

Author

Rheingold, Susan R., primary, Whitlock, James, additional, Tasian, Sarah K., additional, Teachey, David T., additional, Borowitz, Michael J., additional, Liu, Xiaowei, additional, Ahern, Charlotte H., additional, Minard, Charles, additional, Fox, Elizabeth, additional, Weigel, Brenda, additional, and Blaney, Susan, additional

Published
2015
Full Text
View/download PDF

146. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

Author

Raetz, Elizabeth A., primary, Cairo, Mitchell S., additional, Borowitz, Michael J., additional, Lu, Xiaomin, additional, Devidas, Meenakshi, additional, Reid, Joel M., additional, Goldenberg, David M., additional, Wegener, William A., additional, Zeng, Hui, additional, Whitlock, James A., additional, Adamson, Peter C., additional, Hunger, Stephen P., additional, and Carroll, William L., additional

Published
2015
Full Text
View/download PDF

147. Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud

Author

Handgretinger, Rupert, primary, Gore, Lia, additional, Zugmaier, Gerhard, additional, Locatelli, Franco, additional, Zwaan, Christian M., additional, Bhojwani, Deepa, additional, Bader, Peter, additional, O'Brien, Maureen M., additional, Trippett, Tanya M., additional, Brethon, Benoît, additional, Rizzari, Carmelo, additional, Schlegel, Paul Gerhardt, additional, Michel, Gérard, additional, Barnette, Phillip, additional, Messina, Chiara, additional, Hu, Kuolung, additional, Mergen, Noemi, additional, Fischer, Anja, additional, Whitlock, James, additional, and von Stackelberg, Arend, additional

Published
2015
Full Text
View/download PDF

148. Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Author

Whitlock, James, primary, dalla Pozza, Luciano, additional, Goldberg, John M, additional, Silverman, Lewis B., additional, Ziegler, David S., additional, Attarbaschi, Andishe, additional, Brown, Patrick, additional, Gardner, Rebecca A, additional, Gaynon, Paul S., additional, Hutchinson, Raymond J., additional, Marcus, Leigh J., additional, Messinger, Yoav H., additional, Schultz, Kirk R., additional, Vandergiessen, Jeannette, additional, Eckroth, Elena, additional, Locatelli, Franco, additional, Zwaan, C Michel, additional, Wood, Brent L., additional, Sposto, Richard, additional, and Gore, Lia, additional

Published
2014
Full Text
View/download PDF

149. Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Author

Gore, Lia, primary, Locatelli, Franco, additional, Zugmaier, Gerhard, additional, Zwaan, Christian M., additional, Bhojwani, Deepa, additional, Handgretinger, Rupert, additional, Bader, Peter, additional, O'Brien, Maureen M., additional, Trippett, Tanya M., additional, Brethon, Benoît, additional, Rizzari, Carmelo, additional, DuBois, Steven G., additional, Schlegel, Paul Gerhardt, additional, Barnette, Phillip, additional, Messina, Chiara, additional, Hu, Kuolung, additional, Mergen, Noemi, additional, Fischer, Anja, additional, Whitlock, James, additional, and von Stackelberg, Arend, additional

Published
2014
Full Text
View/download PDF

150. Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433

Author

Lew, Glen, primary, Lu, Xiaomin, additional, Yanofsky, Rochelle, additional, Rheingold, Susan R., additional, Whitlock, James, additional, An, Qi, additional, Devidas, Meenakshi, additional, Hastings, Caroline A., additional, Winick, Naomi J., additional, Carroll, William L., additional, Borowitz, Michael J., additional, Hunger, Stephen, additional, and Pulsipher, Michael A., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results